Nonetheless, our study indicates that the inclusion of SGLT2 inhibitors in standard care could be beneficial for managing early stages of CKD, suggesting a potential shift towards more proactive and effective treatment strategies in the future. The gene discussed is SLC5A2; the disease is chronic kidney disease.